Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On July20, 2017, the Board appointed Teresa L. Kline to the Board to serve until the next annual meeting of stockholders, effective August1, 2017. Ms.Kline will also serve as a member of the Compensation Committee and will receive compensation as disclosed in Intersect’s most recent proxy statement filed with the Securities and Exchange Commission on April19, 2017, under the heading “Compensation to Non-Employee Board Members.” Further, Ms.Kline will enter into Intersect’s standard form of indemnification agreement providing for indemnification by Intersect of Ms.Kline in connection with her service as a director, subject to certain limitations.
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.